Mon. 26 Feb 2024, 7:01am ET
Benzinga
Earnings, News
BioCryst Pharma (NASDAQ:BCRX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 26.32 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $93.40 million which beat the analyst consensus estimate of $90.01 million by 3.77 percent. This is a 17.42 percent increase over sales of $79.55 million the same period last year.